Systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue
disease characterized by the production of a large number of autoantibodies, but the etiology
is complex and poorly understood. A range of different platforms have served as screening
methods for the determination of autoantibody specificities over the past few decades.
Proteomic microarray is a relatively new high-throughput technology which is playing an increasingly important
role in autoantibody diagnostics. In this article, we review different platforms for assaying autoantibodies in
SLE, and highlight the use of autoantigen arrays as powerful tools for autoantibody exploration in SLE.
Keywords: Systemic lupus erythematosus, autoantibody profiling, proteomic microarray, biomarker, highthroughput
Rights & PermissionsPrintExport